Bao-Chang Cai

Bao-Chang Cai

Auto-generated profile, based on publicly available information

Bao-Chang Cai

School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2013 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
JCJun Chen
Jun Chen
WLWen-Li Lu
Wen-Li Lu
WGWei Gu
Wei Gu
SLShan-Shan Lu
Shan-Shan Lu
ZCZhi-Peng Chen
Zhi-Peng Chen
BCBao-Chang Cai
Bao-Chang Cai
Introduction: With the incorporation of edge activators into the lipid bilayer structure, elasticity properties are given to liposomes. Regardless of the debate over the precise permeation mechanism of elastic liposomes, these vesicles have been proven to enhance drug permeation into or through skin in most cases. Areas covered: This article provides an overview of the formulation ingredients of elastic liposomes and their relationship with skin permeation behavior. The ingredients are divided into two categories of basic and optional ingredients. The effect of stability on permeation behavior of the vesicles is highlighted. Expert opinion: More attention should be paid to the stability of elastic liposomes. The different stability properties of the elastic liposomes following administration can induce different skin permeation behaviors of the vesicles. It is necessary to select the optimum composition of the elastic liposomes in order to control the stability and permeation behavior of the vesicles into or through the skin. Moreover, for the development of elastic liposomes, particular attention should also be paid to the drug leakage from the vesicles during long-term storage. The application of optional ingredients to improve the stability and/or elasticity of the elastic liposomes is becoming a new trend.

1 October 2013 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
ZCZhi-peng Chen
Zhi-peng Chen
JCJuan Chen
Juan Chen
LWLi Wu
Li Wu
WLWeidong Li
Weidong Li
JCJun Chen
Jun Chen
BCBaochang Cai
Baochang Cai
Objective: To evaluate the potential of hyaluronic acid (HA)-coated bovine serum albumin nanoparticles (BSANPs) as a novel chondrocyte-targeting drug-delivery nanomedicine. Methods: The HA-BSANPs were characterized by dynamic light scattering, transmission electron microscopy, differential scanning calorimetry, and X-ray diffraction. Fluorescence imaging was used to visualize the distribution of nanoparticles after intra-articular injection. The chondrocyte-targeting efficiency and cellular uptake mechanism of HA-BSANPs were investigated using endocytic inhibitors. Results: HA-BSANPs were successfully prepared with HA coating the surface and amorphous drug in the core. Compared with BSANPs, HA-BSANPs exhibited improved uptake by chondrocytes through a receptor-mediated active uptake mechanism. The endocytosis process of BSANPs and HA-BSANPs involved clathrin-mediated endocytosis, caveolae-mediated endocytosis, and macropinocytosis. No apparent thickening or hyperplasia of the synovium was observed in either BSANPs or HA-BSANPs. The HA-BSANPs could reside in the articular cavity of rats for more than 14 days, which was significantly longer than BSANPs. Conclusion: HA-BSANPs are a promising carrier for articular-related diseases due to elongated articular residence and improved chondrocytic accumulation.

13 June 2016 in Journal of Separation Science
Verified
Journal Article
Closed access
PDF file
TZTingting Zhu
Tingting Zhu
XLXiao Liu
Xiao Liu
XWXiaoli Wang
Xiaoli Wang
GCGang Cao
Gang Cao
KQKunming Qin
Kunming Qin
BCBaochang Cai
Baochang Cai

1 November 2014 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
JCJun Chen
Jun Chen
CHChao-Qin He
Chao-Qin He
ALAi-Hua Lin
Ai-Hua Lin
WGWei Gu
Wei Gu
ZCZhi-Peng Chen
Zhi-Peng Chen
BCBao-Chang Cai
Bao-Chang Cai

20 April 2013 in Inflammation
Verified
Journal Article
Closed access
PDF file
LWLi Wu
Li Wu
BCBaochang Cai
Baochang Cai
SZShizhong Zheng
Shizhong Zheng
XLXiao Liu
Xiao Liu
HCHao Cai
Hao Cai
HLHuan Li
Huan Li

19 January 2017 in Molecules
Verified
Journal Article
Open access
PDF file
WPWenxia Pi
Wenxia Pi
XFXiao-Peng Feng
Xiao-Peng Feng
LYLi-Hong Ye
Li-Hong Ye
BCBao-Chang Cai
Bao-Chang Cai
Cornus officinalis and Dioscorea opposita are two traditional Chinese medicines widely used in China for treating diabetes mellitus and its complications, such as diabetic cardiomyopathy. Morroniside (Mor) of Cornus officinalis and diosgenin (Dio) of Dioscorea opposita formed an innovative formula named M + D. The aims of the present study were to investigate myocardial protective effect of M + D on diabetic cardiomyopathy (DCM) through the inhibition of expression levels of caspase-3 protein, and identify the advantage of M + D compared with Mor, Dio, and the positive drug metformin (Met). We detected cell viability, cell apoptosis, intracellular reactive oxygen species (ROS) levels, and the expression levels of Bcl-2, Bax, and caspase-3 protein in rat cardiomyocytes. In result, Mor, Dio, and M + D increased cell viability, inhibited cell apoptosis and decreased ROS levels. Additionally, the expression of Bax and Bcl-2 protein was modulated and the expression levels of caspase-3 protein were markedly decreased. Among the treatment groups, M + D produced the most prominent effects. In conclusion, our data showed for the first time that Mor, Dio, and M + D prevented high glucose (HG)-induced myocardial injury by reducing oxidative stress and apoptosis in rat cardiomyocytes. Among all the groups, M + D produced the strongest effect, while Mor and Dio produced weaker effects.